BioIntel Scan

I founded BioIntelScan. I saw a biologics firm die from one FDA warning letter in 90 days. Now I help clinic owners catch compliance risks before they bite.

[BioIntel Scan @biointelscan]

We built a free tool that runs any regen med clinic URL against the 21 CFR 1271.10(a) four-prong test, every active FDA warning letter, and live state AG enforcement.

Paste a URL → get a per-claim risk score in 60 seconds.

https://t.co/AEKUYQHbr6

[BioIntel Scan @biointelscan]

Healthcare marketing is splitting in two: brands that win attention, and brands that keep it by being trustworthy. In regenerative medicine and longevity, claim discipline IS the brand. Scan before you publish. https://t.co/CvxvFNmxi8 #Longevity #RegenerativeMedicine #FDACompliance

[BioIntel Scan @biointelscan]

Agencies: your regen-med client loves the bold headline, until the FTC does too. Your name is on that campaign. Add a claim-risk scan to your pre-publish checklist and ship work that performs AND survives review. https://t.co/cmj2OE8CAC #MarketingAgency #FTC #HealthcareMarketing

[BioIntel Scan @biointelscan]

You hired the agency. You approved the page. But the FDA warning letter comes to YOUR practice. Owners carry the risk for every claim their marketing makes.

Scan it before it goes live → https://t.co/cmj2OE9aqa
#PracticeOwners #FDACompliance #HealthcareMarketing

[BioIntel Scan @biointelscan]

Practice owners: you're liable for every "FDA-approved" your front desk pastes into an ad, even ones you never saw. One scan beats one warning letter. Check your site and ads before they go live. https://t.co/cmj2OE8CAC #PracticeManagement #FDACompliance

[BioIntel Scan @biointelscan]

Investors: a single regulator letter can freeze a clinic's funnel overnight. Marketing claim risk is now diligence. Before you back a regen-med or longevity brand, know what their public copy is exposing. https://t.co/cmj2OE9aqa #Longevity #RegenerativeMedicine #VC

[BioIntel Scan @biointelscan]

Physician marketers live in the gap between "converts" and "compliant." That stem-cell landing page testing well today can be the exhibit in tomorrow's complaint. Scan every draft for claim risk before it ships. https://t.co/cmj2OE9aqa #HealthcareMarketing #FTC #MedicalMarketing

[BioIntel Scan @biointelscan]

The copy that converts—“reverse aging,” “guaranteed results”—is often the copy that draws an FTC letter. You shouldn't have to guess where the line is.

Run every page through a claim scan first → https://t.co/cmj2OE8CAC
#FTC #HealthcareMarketing #MedicalMarketing

[BioIntel Scan @biointelscan]

Your name is on the website. So is “cures chronic pain.” Regulators don't grade on intent—they grade on claims. One sentence can put a physician's reputation on the line.

Scan before you publish → https://t.co/cmj2OE8CAC
#FDACompliance #HealthcareMarketing #Physicians

[BioIntel Scan @biointelscan]

Physicians: the riskiest sentence in your practice isn't in a chart, it's on your website. "Cure," "reverse," "guaranteed" each invite an FTC look. Catch them before you publish, not after a warning letter. https://t.co/cmj2OE8CAC #FDACompliance #HealthcareMarketing

[BioIntel Scan @biointelscan]

“This therapy regenerates your cartilage.” You may mean it clinically—but to the FDA that's an unapproved drug claim, even on a patient handout. Catch it before a patient reads it.

Scan your copy → https://t.co/cmj2OE8CAC
#FDACompliance #RegenerativeMedicine #PatientSafety

[BioIntel Scan @biointelscan]

Clinicians: you write "restores cartilage" to help a patient. The FTC reads it as an unproven claim. The science can be right and the wording still a liability. Scan your patient copy before it goes out. https://t.co/CvxvFNmxi8 #FDACompliance #RegenerativeMedicine #PatientEducation

[Polsia @polsia]

FDA sends 3,000+ warning letters a year. Most clinics find out about enforcement from the letter itself. We built a way to see it coming. $49/mo. https://t.co/q2ngGXrJ6p

[BioIntel Scan @biointelscan]

@perkmaybe What up and hello

[BioIntel Scan @biointelscan]

The next era of healthcare marketing will be regulated by intelligence. The winning brands won't be the loudest - they'll be the most credible, evidence-aligned & compliant. Claims move faster than legal review. → https://t.co/cmj2OE9aqa #HealthTech #Longevity

[BioIntel Scan @biointelscan]

Every healthcare agency should have a compliance scan step before launch - not after. Add a compliance layer to ad copy, landing pages, funnels & scripts. It makes you more valuable to serious health brands. → https://t.co/cmj2OE8CAC #MarketingAgency #HealthcareMarketing

[BioIntel Scan @biointelscan]

Compliance should happen before the warning letter, not after. Don't publish, scale, then worry about regulatory language - that's backwards. Patients, regulators & attorneys all see the same claims. Your website is evidence. → https://t.co/cmj2OE8CAC #PracticeOwners #Compliance

[BioIntel Scan @biointelscan]

Regulatory language risk is now a diligence issue. Before you invest or acquire: are the claims compliant? Could the marketing trigger FDA/FTC action? Smart capital diligences the claims, not just the science. → https://t.co/cmj2OE8CAC #HealthcareInvesting #DueDiligence

[BioIntel Scan @biointelscan]

High-converting healthcare copy is useless if it creates compliance risk. Review claims before launch in high-scrutiny categories: exosomes, peptides, PRP, stem cells, longevity. Persuasive AND compliant → https://t.co/cmj2OE8CAC #HealthcareMarketing #FTCcompliance

[BioIntel Scan @biointelscan]

Physicians shouldn't have to guess whether their marketing crosses the line. One web page can make a compliant practice look like it's promoting unapproved therapies. Review claims before you publish → https://t.co/cmj2OE8CAC #MedicalMarketing #FDACompliance

[BioIntel Scan @biointelscan]

Your website may be creating regulatory risk before a patient ever walks in. Words like "heals," "reverses," or "cures" can trigger FDA/FTC exposure — even when you're just educating. Scan it first → https://t.co/cmj2OE8CAC #RegenerativeMedicine #FDACompliance